Unimed Pharmaceutical: A type of innovative drug SMR001 eye drops obtained ethical approval for phase III clinical trial.

The announcement by Unimed Pharmaceutical stated that its wholly-owned subsidiary Shandong Yandu Biopharmaceuticals has independently developed an innovative drug, recombinant human nerve growth factor SMR001 eye drops, for the treatment of moderate to severe dry eye syndrome in Phase III key registration clinical trials have obtained approval from the Ethics Committee of Beijing Tongren Hospital affiliated with Capital Medical University. The product has completed major pharmaceutical and clinical Phase II studies, and data has shown it to be effective for moderate to severe dry eye syndrome. The global incidence of dry eye is around 5%-50%, with China accounting for approximately 21%-30%, the market size is growing. However, drug development carries high risks and long cycles, and will not have a significant impact on performance in the short term.